期刊文献+

酪丝亮肽治疗肝癌104例临床观察

下载PDF
导出
摘要 目的探讨酪丝亮肽治疗肝癌用药原理与治疗方法并进行临床观察。方法 104例肝癌患者,均采用酪丝亮肽30 mg加入0.9%生理盐水100 ml,30 d为1个疗程,连续给药6个疗程。观察临床效果。结果 1104例肝癌患者中,6个月生存期限为62例,6个月生存率为59.6%,其余42例均死亡,死亡率为40.4%。结论注射酪丝亮肽无明显毒副作用,耐受性好,能有效延缓或抑制肝细胞癌的药物值得临床应用或推广。
作者 叶建增
出处 《中国实用医药》 2015年第15期182-183,共2页 China Practical Medicine
  • 相关文献

参考文献4

二级参考文献30

  • 1向连滨,向近敏,向家宁,张海燕.巨噬细胞的分子生态学[J].免疫学杂志,1994,10(1):1-7. 被引量:14
  • 2中华外科学会肝脏外科学组.原发性肝癌外科治疗方法的选择(2004年第一次修订)[J].中华普通外科杂志,2005,20(4):262-264. 被引量:12
  • 3ANDREWS PA, ROY D. Nonclinical testing for oncology drug products[M] //TEICHER BA, ANDREWS PA. Anticancer drug development Guide. New Jersey: Humana Press, 2004: 313- 324.
  • 4DEGEORQE JJ, AHN CH, ANDREWS PA, et al. Regulatory considerations for preclinical development of anticancer drugs[J]. Cancer Chemother Pharmacol, 1998, 41(3): 173-185.
  • 5GRILLO-LOPEI AJ. The ODAC chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval [J]. Expert Rev Anticancer Ther, 2005 : 5 (1), 1-5.
  • 6HORSTMANN E, MCCABE MS, GROCHOW L, et al. Risks and benefits of phase 1 ontology trials, 1991 through 2002[J]. N Engl J Med, 2005, 352(9): 895-904.
  • 7BROWN AP, MORRISSEY RL, FAIRCLOTH GT, et al.Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat[J]. Cancer Chemother Pharmacol, 2002, 50(4): 333-340.
  • 8ROBERT J. Place of in vitro models in preclinical evaluation of anticancer drugs[J]. Bull Cancer, 1996, 83(10): 801-808.
  • 9VASSAL G. Methodology and limitations of pre-clinical models for the development of anticarcinogenic chemotherapy combinations[J]. Bull Cancer, 1998, 85 ( 11 ) : 929-934.
  • 10ABRAMS TJ, MURRAY LJ, PESENTI E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer [J]. Mol Cancer Ther, 2003, 2(10): 1011-1021.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部